The 4-variable KFRE score still underestimated the risk for end-stage kidney disease, especially for Black patients. Predicting the risk for end-stage kidney disease (ESKD) using only estimated ...
Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial No significant financial relationships to disclose. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback